Avacincaptad pegol (IVA) and pegcetacoplan (IVP) provide similar visual and anatomical outcomes for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) over 12 months, according to a study.
The study followed 112 patients treated at 3 community-based ophthalmology practices over 12 months.
There were no significant differences between the treatments in terms of GA lesion size progression, visual acuity changes, or exudation rates. However, patients receiving IVA required significantly more injections (9.05 on average) compared to those treated with IVP (5.96, P < 0.01).
These results suggest that although both treatments yield similar visual and anatomical outcomes, IVP may offer the advantage of fewer required injections.
Reference
Rush RB, Klein W, Reinauer RM. Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad Pegol. Clin Ophthalmol. 2025;19:1167-1174. doi: 10.2147/OPTH.S518398. PMID: 40191000; PMCID: PMC11970274.
Related Content
